New drug tested for Tough-to-Treat advanced lung cancers

NCT ID NCT03260491

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called U3-1402 (HER3-DXd) for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors in patients whose cancer has worsened despite previous treatments, including those with specific genetic changes. This is an early-phase trial, so researchers are first learning about the drug's safety and how the body handles it.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, 05505, South Korea
Chung Shan Medical University Hospital

Taichung, 40705, Taiwan
City of Hope

Duarte, California, 91010, United States
Clinica Universidad Navarra(Madrid)

Madrid, 28027, Spain
Clínica Universidad de Navarra (Pamplona)

Pamplona, 31008, Spain
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Gabrail Cancer Center (GCC) - Canton Facility

Canton, Ohio, 44718-2566, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hospital General Universitario Gregorio Maranon (HGUGM)

Madrid, 28007, Spain
Hospital Ramón y Cajal

Madrid, 28034, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)

Madrid, 28050, Spain
Hospital Universitario Quirónsalud Madrid

Madrid, 28223, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Kindai University Hospital

Osaka, 5898511, Japan
Kurume University - Kurume University Hospital - Respiratory Diseases Center

Kurume-Shi, 830-0011, Japan
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology - Hospital Quironsalud Barcelona

Barcelona, 08023, Spain
NYU Langone Health - NYU Medical Oncology Associates

New York, New York, 10016-4744, United States
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus

Kashiwa-Shi, 277-8577, Japan
National Cheng Kung University Hospital

Tainan, 00704, Taiwan
National Taiwan University Hospital

Taipei, 00100, Taiwan
Netherlands Cancer Institute

Amsterdam, 1066 CX, Netherlands
Northwest Medical Specialties

Tacoma, Washington, 98405, United States
Oncology Consultants P.A.

Houston, Texas, 77030, United States
Pacific Shores Medical Group

Long Beach, California, 90813, United States
Samsung Medical Center

Seoul, 06351, South Korea
Sarah Cannon Research Institute/Tennesse Oncology

Nashville, Tennessee, 37203, United States
Seoul National University Hospital

Seoul, 03080, South Korea
Shizuoka Cancer Center

Shizuoka, 4118777, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)

Tokyo, 1358550, Japan
University of California San Diego

La Jolla, California, 92093, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232-1301, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC)